Literature DB >> 15198850

D-galactosamine lethality model: scope and limitations.

Richard Silverstein1.   

Abstract

D-Galactosamine (D-galN) is well established as sensitizing mice and other animals to the lethal effects of TNF, specifically, and by several orders of magnitude. Protection by anti-TNF neutralizing antibody is complete, as is (metabolically-based) protection by uridine. Sensitization occurs regardless of the origin of the released TNF, whether it is released from macrophages and/or T-cells. The same is true for the challenging agent which leads to the release of TNF, whether it is endotoxin, a superantigen, lipoprotein, bacterial DNA, or bacteria, either killed or proliferating. Most studies have utilized endotoxin as the challenging agent, and more than 70 agents have been reported to confer protection against LPS and/or TNF challenge in the model. The model has provided new insight regarding modes of protection, including from dexamethasone, which protects against challenge from LPS but not from challenge by TNF. The D-galN lethality model has also been used to test for synergistic behavior between different bacterial components, and to test for lethality when only small amounts of the challenging agent are available (lipid A chemistry).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198850     DOI: 10.1179/096805104225004879

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  59 in total

1.  Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.

Authors:  Anna Simon; Heiyoung Park; Ravikanth Maddipati; Adrian A Lobito; Ariel C Bulua; Adrianna J Jackson; Jae Jin Chae; Rachel Ettinger; Heleen D de Koning; Anthony C Cruz; Daniel L Kastner; Hirsh Komarow; Richard M Siegel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Whole-body deletion of LPS-induced TNF-α factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis.

Authors:  Jamie C Merrill; Jian You; Cara Constable; Susan E Leeman; Salomon Amar
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

4.  A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model.

Authors:  Li Ma; Haiyan Gong; Haiyan Zhu; Qing Ji; Pei Su; Peng Liu; Shannan Cao; Jianfeng Yao; Linlin Jiang; Mingzhe Han; Xiaotong Ma; Dongsheng Xiong; Hongbo R Luo; Fei Wang; Jiaxi Zhou; Yuanfu Xu
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

5.  Galactose protects hepatocytes against TNF-α-induced apoptosis by promoting activation of the NF-κB signaling pathway in acute liver failure.

Authors:  Yanmin Liu; Liuluan Zhu; Shuntao Liang; Shanshan Yao; Rui Li; Sanhai Liu; Yaluan Ma; Xiaobing Zhou; Jinliang Zhang; Hui Zeng; Xianbo Wang
Journal:  Lab Invest       Date:  2015-03-09       Impact factor: 5.662

6.  Human leukocyte antigen class II transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome.

Authors:  Ashenafi Y Tilahun; Eric V Marietta; Tsung-Teh Wu; Robin Patel; Chella S David; Govindarajan Rajagopalan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  Identification and characterization of kava-derived compounds mediating TNF-alpha suppression.

Authors:  Michael P Pollastri; Adrian Whitty; Jamie Cassidy Merrill; Xiaoren Tang; Trent D Ashton; Salomon Amar
Journal:  Chem Biol Drug Des       Date:  2009-06-16       Impact factor: 2.817

8.  Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation.

Authors:  Myriam Aouadi; Gregory J Tesz; Sarah M Nicoloro; Mengxi Wang; My Chouinard; Ernesto Soto; Gary R Ostroff; Michael P Czech
Journal:  Nature       Date:  2009-04-30       Impact factor: 49.962

9.  Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure.

Authors:  Hiroshi Yagi; Biju Parekkadan; Kazuhiro Suganuma; Alejandro Soto-Gutierrez; Ronald G Tompkins; Arno W Tilles; Martin L Yarmush
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

10.  Hyper innate responses in neonates lead to increased morbidity and mortality after infection.

Authors:  Jie Zhao; Kwang Dong Kim; Xuanming Yang; Sogyong Auh; Yang-Xin Fu; Hong Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.